# Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

> **NCT06546423** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- Human Metapneumovirus
- Human Parainfluenza Virus Type 3

## Interventions

- **BIOLOGICAL:** B/HPIV3/HMPV-PreF-A vaccine
- **BIOLOGICAL:** B/HPIV3/HMPV-F-B365 vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06546423
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-12
- **Primary completion:** 2025-06-04
- **Final completion:** 2025-06-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06546423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06546423, "Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06546423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*